|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemminki A, Oksanen M and
Merisalo-Soikkeli M: Oncolytic virotherapy trials-letter. Clin
Cancer Res. 19:4541–4542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Russell SJ, Peng KW and Bell JC: Oncolytic
virotherapy. Nat Biotechnol. 30:658–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maroun J, Muñoz-Alía M, Ammayappan A,
Schulze A, Peng KW and Russell S: Designing and building oncolytic
viruses. Future Virol. 12:193–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukuhara H, Ino Y and Todo T: Oncolytic
virus therapy: A new era of cancer treatment at dawn. Cancer Sci.
107:1373–1379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mineta T, Rabkin SD, Yazaki T, Hunter WD
and Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for
the treatment of malignant gliomas. Nat Med. 1:938–943. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Delwar ZM, Liu G, Kuo Y, Lee C, Bu L,
Rennie PS and Jia WW: Tumour-specific triple-regulated oncolytic
herpes virus to target glioma. Oncotarget. 7:28658–28669. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Longo SL, Griffith C, Glass A, Shillitoe
EJ and Post DE: Development of an oncolytic herpes simplex virus
using a tumor-specific HIF-responsive promoter. Cancer Gene Ther.
18:123–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee CY, Bu LX, Rennie PS and Jia WW: An
HSV-1 amplicon system for prostate-specific expression of ICP4 to
complement oncolytic viral replication for in vitro and in vivo
treatment of prostate cancer cells. Cancer Gene Ther. 14:652–660.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Streby KA, Geller JI, Currier MA, Warren
PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K,
Dishman DJ, et al: Intratumoral injection of HSV1716, an oncolytic
herpes virus, is safe and shows evidence of immune response and
viral replication in young cancer patients. Clin Cancer Res.
23:3566–3574. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Markert JM, Razdan SN, Kuo HC, Cantor A,
Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM,
et al: A phase 1 trial of oncolytic HSV-1, G207, given in
combination with radiation for recurrent GBM demonstrates safety
and radiographic responses. Mol Ther. 22:1048–1055. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geevarghese SK, Geller DA, de Haan HA,
Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY,
Tanabe KK and Tawfik H: Phase I/II study of oncolytic herpes
simplex virus NV1020 in patients with extensively pretreated
refractory colorectal cancer metastatic to the liver. Hum Gene
Ther. 21:1119–1128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andtbacka RH, Kaufman HL, Collichio F,
Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I,
Agarwala SS, et al: Talimogene laherparepvec improves durable
response rate in patients with advanced melanoma. J Clin Oncol.
33:2780–2788. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deguchi T, Shikano T, Kasuya H, Nawa A,
Fujiwara S, Takeda S, Gewen T, Sahin TT, Yamada S, Kanzaki A, et
al: Combination of the tumor angiogenesis inhibitor bevacizumab and
intratumoral oncolytic herpes virus injections as a treatment
strategy for human gastric cancers. Hepatogastroenterology.
59:1844–1850. 2012.PubMed/NCBI
|
|
17
|
Wong J, Kelly K, Mittra A, Gonzalez SJ,
Song KY, Simpson G, Coffin R and Fong Y: A third-generation
herpesvirus is effective against gastroesophageal cancer. J Surg
Res. 163:214–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sugawara K, Iwai M, Yajima S, Tanaka M,
Yanagihara K, Seto Y and Todo T: Efficacy of a Third-generation
oncolytic herpes virus G47Δ in advanced stage models of human
gastric cancer. Mol Ther Oncolytics. 17:205–215. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsuji T, Nakamori M, Iwahashi M, Nakamura
M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T and Yamaue
H: An armed oncolytic herpes simplex virus expressing
thrombospondin-1 has an enhanced in vivo antitumor effect against
human gastric cancer. Int J Cancer. 132:485–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu L, Wu W, Zhu G, Liu L, Guan G, Li X,
Jin N and Chi B: Therapeutic efficacy of an hTERT promoter-driven
oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Int J Mol Med. 30:747–754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yano S, Takehara K, Tazawa H, Kishimoto H,
Urata Y, Kagawa S, Fujiwara T and Hoffman RM: Therapeutic
cell-cycle-decoy efficacy of a telomerase-dependent adenovirus in
an orthotopic model of chemotherapy-resistant human stomach
carcinomatosis peritonitis visualized with FUCCI imaging. J Cell
Biochem. 118:3635–3642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seimiya H: Crossroads of telomere biology
and anticancer drug discovery. Cancer Sci. 111:3089–3099. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Chen X, Li L, Zhou Y, Wang C and
Hou S: The association between telomere length and cancer
prognosis: Evidence from a meta-analysis. PLoS One.
10:e01331742015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watson JD: Origin of concatemeric T7 DNA.
Nat New Biol. 239:197–201. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hiyama E, Gollahon L, Kataoka T, Kuroi K,
Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA and Shay JW:
Telomerase activity in human breast tumors. J Natl Cancer Inst.
88:116–122. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kyo S, Kanaya T, Ishikawa H, Ueno H and
Inoue M: Telomerase activity in gynecological tumors. Clin Cancer
Res. 2:2023–2028. 1996.PubMed/NCBI
|
|
28
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant tumours. 7th edition.
Wiley-Blackwell; Hoboken, NJ, USA: 2011
|
|
29
|
Lü MH, Deng JQ, Cao YL, Fang DC, Zhang Y
and Yang SM: Prognostic role of telomerase activity in gastric
adenocarcinoma: A meta-analysis. Exp Ther Med. 3:728–734. 2012.
View Article : Google Scholar
|
|
30
|
Campagna D, Cope L, Lakkur SS, Henderson
C, Laheru D and Iacobuzio-Donahue CA: Gene expression profiles
associated with advanced pancreatic cancer. Int J Clin Exp Pathol.
1:32–43. 2008.PubMed/NCBI
|
|
31
|
Meinhold-Heerlein I, Stenner-Liewen F,
Liewen H, Kitada S, Krajewska M, Krajewski S, Zapata JM, Monks A,
Scudiero DA, Bauknecht T and Reed JC: Expression and potential role
of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol.
158:1335–1344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seethala RR, Gooding WE, Handler PN,
Collins B, Zhang Q, Siegfried JM and Grandis JR:
Immunohistochemical analysis of phosphotyrosine signal transducer
and activator of transcription 3 and epidermal growth factor
receptor autocrine signaling pathways in head and neck cancers and
metastatic lymph nodes. Clin Cancer Res. 14:1303–1309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shimizu A, Hirono S, Tani M, Kawai M,
Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S and
Yamaue H: Coexpression of MUC16 and mesothelin is related to the
invasion process in pancreatic ductal adenocarcinoma. Cancer Sci.
103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Campbell EJ, McDuff E, Tatarov O, Tovey S,
Brunton V, Cooke TG and Edwards J: Phosphorylated c-Src in the
nucleus is associated with improved patient outcome in ER-positive
breast cancer. Br J Cancer. 99:1769–1774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cappia S, Righi L, Mirabelli D, Ceppi P,
Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M:
Prognostic role of osteopontin expression in malignant pleural
mesothelioma. Am J Clin Pathol. 130:58–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Todo T, Martuza RL, Rabkin SD and Johnson
PA: Oncolytic herpes simplex virus vector with enhanced MHC class I
presentation and tumor cell killing. Proc Natl Acad Sci USA.
98:6396–6401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu X, Nakamori M, Tao L, Amato R and Zhang
X: Antitumor effects of two newly constructed oncolytic herpes
simplex viruses against renal cell carcinoma. Int J Oncol.
30:1561–1567. 2007.PubMed/NCBI
|
|
38
|
Morikawa T, Sugiyama A, Kume H, Ota S,
Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M and Aburatani
H: Identification of Toll-like receptor 3 as a potential
therapeutic target in clear cell renal cell carcinoma. Clin Cancer
Res. 13:5703–5709. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morikawa T, Hino R, Uozaki H, Maeda D,
Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of
ribonucleotide reductase M2 subunit in gastric cancer and effects
of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Passer BJ, Wu CL, Wu S, Rabkin SD and
Martuza RL: Analysis of genetically engineered oncolytic herpes
simplex viruses in human prostate cancer organotypic cultures. Gene
Ther. 16:1477–1482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nordlund P and Reichard P: Ribonucleotide
reductases. Annu Rev Biochem. 75:681–706. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hsieh YY, Chou CJ, Lo HL and Yang PM:
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a
ribonucleotide reductase M2 inhibitor to treat human colorectal
cancer. Cell Death Discov. 2:160272016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Eriksson S and Martin DW Jr:
Ribonucleotide reductase in cultured mouse lymphoma cells. Cell
cycle-dependent variation in the activity of subunit protein M2. J
Biol Chem. 256:9436–9440. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen CH and Chen RJ: Prevalence of
telomerase activity in human cancer. J Formos Med Assoc.
110:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu Z, Li Q, Li K, Chen L, Li W, Hou M,
Liu T, Yang J, Lindvall C, Björkholm M, et al: Telomerase reverse
transcriptase promotes epithelial-mesenchymal transition and stem
cell-like traits in cancer cells. Oncogene. 32:4203–4213. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ruden M and Puri N: Novel anticancer
therapeutics targeting telomerase. Cancer Treat Rev. 39:444–456.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoo J, Park SY, Kang SJ, Kim BK, Shim SI
and Kang CS: Expression of telomerase activity, human telomerase
RNA, and telomerase reverse transcriptase in gastric
adenocarcinomas. Mod Pathol. 16:700–707. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yano S, Tazawa H, Hashimoto Y, Shirakawa
Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y,
et al: A genetically engineered oncolytic adenovirus decoys and
lethally traps quiescent cancer stem-like cells in S/G2/M phases.
Clin Cancer Res. 19:6495–6505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Watanabe M, Kagawa S, Kuwada K, Hashimoto
Y, Shigeyasu K, Ishida M, Sakamoto S, Ito A, Kikuchi S, Kuroda S,
et al: Integrated fluorescent cytology with nano-biologics in
peritoneally disseminated gastric cancer. Cancer Sci.
109:3263–3271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ishikawa W, Kikuchi S, Ogawa T, Tabuchi M,
Tazawa H, Kuroda S, Noma K, Nishizaki M, Kagawa S, Urata Y and
Fujiwara T: Boosting replication and penetration of oncolytic
adenovirus by paclitaxel eradicate peritoneal metastasis of gastric
cancer. Mol Ther Oncolytics. 18:262–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nakatake R, Kaibori M, Nakamura Y, Tanaka
Y, Matushima H, Okumura T, Murakami T, Ino Y, Todo T and Kon M:
Third-generation oncolytic herpes simplex virus inhibits the growth
of liver tumors in mice. Cancer Sci. 109:600–610. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matsushima H, Kaibori M, Hatta M, Ishizaki
M, Nakatake R, Okumura T, Yoshii K and Todo T: Efficacy of a
third-generation oncolytic herpes simplex virus in neuroendocrine
tumor xenograft models. Oncotarget. 10:7132–7141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lam JT, Kanerva A, Bauerschmitz GJ,
Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Liu B, Wang M, Barnes
MN, et al: Inter-patient variation in efficacy of five oncolytic
adenovirus candidates for ovarian cancer therapy. J Gene Med.
6:1333–1342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ribas A, Dummer R, Puzanov I, VanderWalde
A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J,
Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T
cell infiltration and improves Anti-PD-1 immunotherapy. Cell.
174:1031–1032. 2018. View Article : Google Scholar : PubMed/NCBI
|
